Carlo Cernetti

Carlo Cernetti

Auto-generated profile, based on publicly available information

Carlo Cernetti

Cardiology Unit, Cardio-Neuro-Vascular Department, Ca’ Foncello Hospital Azienda N 2 Marca Trevigiana, Treviso, Italy (E.G., L.F., C.C.).

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Clinical Cardiology
Verified
Journal Article
Open access
Leonardo De LucaLeonardo De Luca
Leonardo De Luca
Paolo CalabròPaolo Calabrò
Paolo Calabrò
FCFabio Chirillo
Fabio Chirillo
CRCristina Rolfo
Cristina Rolfo
AMAlberto Menozzi
Alberto Menozzi
AGARCANGELO study group
ARCANGELO study group
Background: The itAlian pRospective Study on CANGrELOr (ARCANGELO) was aimed to assess the safety of using cangrelor during percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) in the daily practice.Hypothesis: The safety of cangrelor after the transition to oral P2Y12 inhibitors was evaluated as the incidence of bleeding outcomes in the 30 days following PCI according to postauthorization safety study guidelines.Methods: Adults with ACS who were treated with cangrelor in one of the 28 centers involved in the study. Patients who consented to participate were followed in the 30 days following their PCI. Bleedings (Bleeding Academic Research Consortium [BARC] classification), major adverse cardiac events (MACEs), and adverse events were recorded. The interim results at two‐thirds of the enrollment period are presented.Results: A total of 17 bleedings were observed in the 320 patients who completed the study at this stage. All bleedings were classified as BARC Type 1–2, except for one case of Type 3a (vessel puncture site hematoma). Four patients experienced MACEs (2 acute myocardial infarctions, 1 sudden cardiac death, 1 noncardiovascular death due to respiratory distress, and multiorgan failure). None of the bleedings was rated as related to cangrelor.Conclusions: The interim results of the ARCANGELO study provide a preliminary confirmation that the use of cangrelor on patients with ACS undergoing PCI is not associated with severe bleedings.

12 April 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
PMPiero Montorsi
Piero Montorsi
BCBernardo Cortese
Bernardo Cortese
CCCarlo Cernetti
Carlo Cernetti
DLDavide Lanzellotti
Davide Lanzellotti
GPGaetano Di Palma
Gaetano Di Palma
ACAlberto Cremonesi
Alberto Cremonesi

1 October 2021 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
ABAlberto Barioli
Alberto Barioli
NPNicola Pellizzari
Nicola Pellizzari
Luca FaveroLuca Favero
Luca Favero
CCCarlo Cernetti
Carlo Cernetti
Background: The optimal treatment of aneurysmal or ectatic culprit vessels in the setting of acute myocardial infarction is still matter of debate, as revascularization with either percutaneous intervention or surgery is associated with low procedural success and poor outcomes. Case summary: We report the case of a 55-year-old male patient, admitted for inferior ST-elevation myocardial infarction, who underwent successful percutaneous implantation of a micro-mesh self-expanding nitinol carotid stent in a right coronary aneurysm with intravascular ultrasonography measured diameter of 9 mm and massive thrombus apposition. Discussion: The technical characteristics of the micro-mesh self-expanding nitinol carotid stent allow for adequate plaque coverage and good apposition even in large vessels, making this device particularly suitable for the treatment of coronary lesions with high thrombus burden, when severe coronary ectasia or aneurysms are present.

2 June 2025 in Current Vascular Pharmacology
Verified
Journal Article
Open access
PDF file
Leonardo De LucaLeonardo De Luca
Leonardo De Luca
Paolo CalabròPaolo Calabrò
Paolo Calabrò
PCPiera Capranzano
Piera Capranzano
ENElisa Nicolini
Elisa Nicolini
CMCiro Mauro
Ciro Mauro
Plinio CirilloPlinio Cirillo
Plinio Cirillo
Aims: The present analysis of the ARCANGELO study aims to investigate the effect of switching to different oral P2Y12 inhibitors when using cangrelor during PCIs in patients with ACS. Methods: Out of the 995 patients meeting the criteria for this investigation, 138 transitioned to Clopidogrel (CLO), 127 to rasugrel (PRA), and 730 to Ticagrelor (TICA). Compared to the patients on PRA or TICA, users of CLO were older (median (Q1-Q3) 74(64-81) years CLO, 59(54-65) years PRA, 65(56-73) TICA; p<0.0001), had more comorbidities (37.0% CLO, 17.3% PRA, 18.9% TICA, p<0.0001), and had more frequently an NSTEMI diagnosis (68.1% CLO vs 33.1% PRA vs 35.9% TICA, p<0.0001). Results: Five moderate bleeds were recorded without any severe episodes. There were no significant differences in the bleeding rate when switching to the different oral P2Y12 inhibitors (2.2% CLO, 5.3% TICA, 7.9% PRA, p = 0.0705) while different incidences of MACEs (4.3% CLO, 1.1% TICA, 0% PRA, p = 0.0113) and NACEs (4.3% CLO, 1.8% TICA, 0% PRA, p=0.0321) were observed during the 30 days of the study. Conclusion: The use of cangrelor and the switch to any oral P2Y12 inhibitor in compliance with the EU SmPC is safe, with a low risk of ischemic events in routine clinical practice.

12 May 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
TFTommaso Fabris
Tommaso Fabris
FAFederico Arturi
Federico Arturi
ABAndrea Buono
Andrea Buono
CBChiara De Biase
Chiara De Biase
MBMichele Bellamoli
Michele Bellamoli
GTGiuseppe Tarantini
Giuseppe Tarantini
BACKGROUND: Evidence regarding prosthesis–patient mismatch (PPM), measured (mPPM), and predicted (pPPM), after transcatheter aortic valve replacement in bicuspid aortic valve stenosis remains limited. This study sought to evaluate the incidence, predictors, and prognostic implications of mPPM and pPPM in patients with Sievers type 1 bicuspid aortic valve undergoing transcatheter aortic valve replacement. METHODS: The AD-HOC registry is a retrospective, multicenter study including 781 patients with severe aortic stenosis and bicuspid aortic valve treated with transcatheter aortic valve replacement between 2016 and 2023 across 24 centers. PPM was defined according to Valve Academic Research Consortium-3 criteria. The primary outcome was all-cause mortality. RESULTS: Moderate-to-severe mPPM was more frequent than pPPM (22% versus 8%; P <0.001). Balloon-expandable valves were independently associated with both mPPM and pPPM, while smaller valve size and supra-annular sizing predicted only pPPM. During a mean follow-up of 621±470 days, neither mPPM nor pPPM was associated with mortality in the overall cohort. Among patients with a small annulus (≤430 mm 2 ; n=145), pPPM occurrence was significantly higher (19% versus 5.5%; P <0.001) and was associated with increased all-cause mortality, but not with cardiovascular mortality. CONCLUSIONS: In patients with Sievers type 1 bicuspid aortic valve undergoing transcatheter aortic valve replacement, pPPM occurred less frequently than mPPM and was predominantly driven by anatomic characteristics and sizing strategies. Although pPPM was associated with increased all-cause mortality among patients with small annuli, this association did not extend to cardiovascular mortality and should be considered hypothesis-generating. Further prospective investigations are warranted to better delineate the impact of anatomic constraints on clinical outcomes in this anatomically challenging subset.

1 January 2021 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
DGDavide Genovese
Davide Genovese
RZRoberto Zecchel
Roberto Zecchel
ADAlessandro Daniotti
Alessandro Daniotti
PPPiergiuseppe Piovesana
Piergiuseppe Piovesana
CCCarlo Cernetti
Carlo Cernetti
Korean Circulation Journal 대한심장학회지 순환기 Genovese D, et al. Korean Circ J. 2021 Aug;51(8):710-711. https://doi.org/10.4070/kcj.2021.0146